[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524118":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":11,"centralContacts":26,"locations":32,"responsibleParty":52,"collaborators":11,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":11,"enrollmentInfo":63,"targetDuration":11,"studyType":66,"phases":67,"briefSummary":70,"conditions":71,"keywords":11,"overallStatus":35,"whyStopped":11,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Shanghai Hengrui Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SHR-A1912 combined with R-Chemo (Phase 1b)","EXPERIMENTAL",null,[13],"Drug: SHR-A1912; R-Chemo",{"label":15,"type":10,"description":11,"interventionNames":16},"SHR-A1912 combined with R-Chemo (Phase 2)",[13],[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","SHR-A1912; R-Chemo","SHR-A1912 combined with R-Chemo: SHR-A1912 + R-Chemo (Rituximab + Chemotherapy) (Phase 1b)",[9],{"type":19,"name":20,"description":24,"armGroupLabels":25,"otherNames":11},"SHR-A1912 combined with R-Chemo: SHR-A1912 (RP2D) + R-Chemo (Rituximab + Chemotherapy) (Phase 2)",[15],[27],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"Zhenyu Xiao, Medical Director","CONTACT","021-61053363","zhenyu.xiao.zx7@hengrui.com",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Beijing Cancer Hospital","RECRUITING","Beijing","Beijing Municipality","100142","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":50,"phoneExt":11,"email":51},"Yuqin Song, Doctor","+86-13683398726","songyuqin622@163.com",{"type":53,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100524118","phase-1-a-trial-of-shr-a1912-combined-with-other-therapies-in-b-cell-non-hodgkin-s-lymphoma-100524118",false,"NCT06104553","A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma","A Phase Ib\u002FII Study of SHR-A1912 Combined With Other Therapies in Patients With B-cell Non-Hodgkin 's Lymphoma","Inclusion Criteria:\n\n1. Age greater than or equal to18 years old;\n2. Eastern Cooperative Oncology Group (ECOG) performance status is 0 to 1;\n3. Life expectancy \\>3 months;\n4. Histologically confirmed B-cell B-cell non-Hodgkin's lymphoma;\n5. Previous systematic anti-tumor therapy should meet the following requirements: 1) Relapsed and\u002For refractory disease after at least one (≥ 1) line of prior systemic therapy (relapsed\u002Frefractory cohort); 2) Previously untreated (naïve cohort).\n6. At least one measurable nodal lesion, defined as \\> 1.5 cm in its longest dimension, or one measurable extra nodal lesion, defined as \\> 1.0 cm in its longest diameter.\n\nExclusion Criteria:\n\n1. Received autologous stem cell transplantation within 12 weeks before the first study treatment; previously received allogeneic stem cell transplantation; received Car-T cell therapy within 12 weeks before the first study treatment;\n2. History of recent major surgery or severe trauma within 4 weeks before the first study treatment;\n3. Received anti-tumour treatment within 2 weeks before the first study treatment;\n4. Central nervous system (CNS) infiltration;\n5. Active infection with HBV or HCV;\n6. History of immunodeficiency, including HIV serotest positive, or other acquired or congenital immunodeficiency diseases, and active tuberculosis;\n7. Active infection or unexplained fever\\>38.5℃;\n8. History of severe cardiovascular disease.","ALL","18 Years",{"count":64,"type":65},132,"ESTIMATED","INTERVENTIONAL",[68,69],"PHASE1","PHASE2","This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.",[72],"B-cell Non-Hodgkin's Lymphoma","2023-12-20",{"date":75,"type":76},"2023-12-27","ACTUAL",{"date":78,"type":76},"2023-11-17",{"date":80,"type":65},"2026-06",{"name":5,"class":6},1]